Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: An open-lable, single-arm, phase II study

被引：1
作者：
Zhou, H. [1 ]
Long, B. [2 ]
Yu, Z. [3 ]
Zhu, J. [2 ]
Yang, H. [4 ]
Zhang, W. [3 ]
Guan, X. [5 ]
Zhang, G. [2 ]
Li, L. [2 ]
Luo, C. [2 ]
Cao, H. [2 ]
Zhang, S. [2 ]
Chen, S. [2 ]
He, Q. [2 ]
Gan, S. [2 ]
Zhou, L. [2 ]
Jiang, X. [2 ]
Shi, W.
Huang, Z. [5 ]
Mao, J. [2 ]
Dong, C. [6 ]
Jiao, Z. [2 ]
机构：
[1] Gansu Prov Canc Hosp, Dept Abdominal Surg, Lanzhou, Peoples R China
[2] Lanzhou Univ Second Hosp, Dept Gen Surg, Lanzhou, Peoples R China
[3] Lanzhou Univ Second Hosp, Dept Radiol, Lanzhou, Peoples R China
[4] Lanzhou Univ Second Hosp, Cuiying Cent Lab, Lanzhou, Peoples R China
[5] Lanzhou Univ Second Hosp, Dept Gastroenterol, Lanzhou, Peoples R China
[6] Lanzhou Univ Second Hosp, Dept Pathol, Lanzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.202
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-146
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
    Jiang, Haiping
    Yu, Xiongfei
    Li, Ning
    Kong, Mei
    Ma, Zhimin
    Zhou, Donghui
    Wang, Weibin
    Wang, Haohao
    Wang, Haiyong
    He, Kuifeng
    Li, Zhongqi
    Lu, Yimin
    Zhang, Jing
    Zhao, Kui
    Zhang, Yafei
    Xu, Nong
    Li, Ziran
    Liu, Ying
    Wang, Yan
    Wang, Yisen
    Teng, Lisong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [22] Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
    He, J.
    Yang, Y.
    Zhou, S.
    Zhang, B.
    Han, Z.
    Wu, T.
    Qiao, Q.
    Yang, H.
    He, X.
    Wang, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1549 - S1549
  • [23] Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial
    Wei, Jia
    Lu, Xiaofeng
    Liu, Qin
    Fu, Yao
    Liu, Song
    Li, Lin
    Liu, Fangcen
    Fan, Xiangshan
    Yang, Ju
    Yang, Yang
    Zhao, Yang
    Guan, Wenxian
    Liu, Baorui
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2007 - 2015
  • [24] Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.
    Ma, Fei
    Luo, Suxia
    Zhang, Bin
    Ma, Qi
    Ji, Sheqing
    Zhang, Zhandong
    Zhang, Yonglei
    Yang, Wei
    Peng, Liangqun
    Guo, Dandan
    Ren, Jinjun
    Zhang, Yuan
    Su, Yueyue
    Li, Jing
    Liu, Wentao
    Huang, Jinxi
    Yuan, Weiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial
    Shi, Jinming
    Li, Ning
    Tang, Yuan
    Jiang, Liming
    Yang, Lin
    Wang, Shulian
    Song, Yongwen
    Liu, Yueping
    Fang, Hui
    Lu, Ningning
    Qi, Shunan
    Chen, Bo
    Li, Ziyu
    Liu, Shixin
    Wang, Jun
    Wang, Wenling
    Zhu, Suyu
    Yang, Jialin
    Li, Yexiong
    Zhao, Dongbing
    Jin, Jing
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [26] Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy
    Min, L. Z.
    Liu, N.
    Zhou, Y.
    Niu, Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1106 - S1106
  • [27] Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial
    Jinming Shi
    Ning Li
    Yuan Tang
    Liming Jiang
    Lin Yang
    Shulian Wang
    Yongwen Song
    Yueping Liu
    Hui Fang
    Ningning Lu
    Shunan Qi
    Bo Chen
    Ziyu Li
    Shixin Liu
    Jun Wang
    Wenling Wang
    Suyu Zhu
    Jialin Yang
    Yexiong Li
    Dongbing Zhao
    Jing Jin
    BMC Gastroenterology, 22
  • [28] SOX combined with tislelizumab and low-dose radiation therapy for the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase Ib/II clinical trial
    Zhang, Peng-Fei
    Chen, Ye
    Li, Wen-Ke
    Luo, Zhu-Mei
    Chen, Ji
    Qian, Kun
    Chen, Xiao-Dong
    Wang, Mo-Jin
    Liu, Ming
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [29] Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety.
    Liu, Ying
    Han, Guangsen
    Li, Hongle
    Zhao, Yuzhou
    Li, Zhi
    Zhuang, Jing
    Wang, Gangcheng
    Li, Baodong
    Wang, Jinbang
    Li, Zhimeng
    Xia, Qingxin
    Zhang, Chengjuan
    Yu, Juan
    Li, Ke
    Xu, Shuning
    Qiao, Lei
    Kuang, Gaizhen
    Li, Danyang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Surufatinib plus sintilimab in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, single-center phase II trial.
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Lu, Yun-Xin
    Bai, Bing
    Zhang, Yang
    Wang, Zhi-Qiang
    Liu, Yu
    Chen, Jian-Wen
    Wang, Feng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 358 - 358
12345